公开(公告)号：US20210079074A1

公开(公告)日：2021-03-18

申请号：US16943123

申请日：2020-07-30

Applicant: Alector LLC

Inventor： Jeonghoon SUN ,  Wei-Hsien HO ,  Muhammad A. ALHAWAGRI ,  Philip Ling KONG ,  Herve RHINN ,  Hua LONG ,  Karpagam SRINIVASAN ,  Ananya MITRA ,  Daniel P. BERMINGHAM ,  Klaus-Dieter HEGER ,  Santiago Viveros SALAZAR ,  Francesca CIGNARELLA ,  Ilaria TASSI ,  Tina SCHWABE ,  Angie Grace YEE ,  Arnon ROSENTHAL

IPC: C07K16/18

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20240076362A1

公开(公告)日：2024-03-07

申请号：US18310207

申请日：2023-05-01

Applicant: Alector LLC

Inventor： Jeonghoon SUN ,  Wei-Hsien HO ,  Muhammad A. ALHAWAGRI ,  Philip Ling KONG ,  Herve RHINN ,  Hua LONG ,  Karpagam SRINIVASAN ,  Ananya MITRA ,  Daniel P. BERMINGHAM ,  Klaus-Dieter HEGER ,  Santiago Viveros SALAZAR ,  Francesca CIGNARELLA ,  Ilaria TASSI ,  Tina SCHWABE ,  Angie Grace YEE ,  Arnon ROSENTHAL

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230159637A1

公开(公告)日：2023-05-25

申请号：US17801776

申请日：2021-02-23

Applicant: Alector LLC ,  Washington University

Inventor： Francesca CIGNARELLA ,  Fabia FILIPELLO ,  Bryan BOLLMAN ,  Arnon ROSENTHAL ,  Tina SCHWABE ,  Ilaria TASSI ,  Laura PICCIO

IPC: C07K16/28 ,  A61P25/28

CPC classification number: C07K16/2803 ,  A61P25/28 ,  A61K2039/505

Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.